Fatty Liver Alliance’s Post

🌟 CIMA Sciences, LLC and OWL Metabolomics will attend at the upcoming Emerging Topic Conference: Precision Medicine in MASLD, which is organized by American Association for the Study of Liver Diseases (AASLD) in Las Vegas the 8-9th of March, in which CIMA Sciences, LLC will be sponsoring the coffee break. 🔬 Cristina Alonso, the Metabolomics Services Manager of OWL Metabolomics, will deliver a talk on advances in metabolomics and hepatology. Don’t miss this opportunity! 🤝 Meet us in the event to discover more about OWLiver® non-invasive diagnostic tool and how we're contributing to non-invasive liver health diagnostics to fight #MASH and #MASLD.   #MASEF #Metabolomics #OWLMetabolomics

🧪 We are thrilled to announce that OWL Metabolomics has contributed to a groundbreaking study published in the United European Gastroenterology Journal! 🧬 In collaboration with Dr. Paula Iruzubieta, Dr. Javier Crespo, and researchers from 7 Spanish hospitals, our scientific team has made significant strides in the field of hepatology. The study, titled "One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis in high‐risk population," highlights the effectiveness of our OWLiver Panel, which includes the innovative MASEF Score. This blood-based test has demonstrated high accuracy and performance, offering a powerful tool for diagnosing MASH and liver fibrosis, particularly in high-risk populations. Discover more about this important research and its potential impact on liver disease diagnosis. 🔗Read the full study here: https://lnkd.in/dTCXmNTG #Hepatology #Metabolomics #LiverHealth #MedicalResearch #OWLMetabolomics #HealthcareInnovation

Interesting news in the world of liver research! Researchers at the First Hospital of Jilin University have discovered a new organelle in liver cells called the mitochondria-lysosome-related organelle (MLRO), shedding light on chronic liver diseases like metabolic dysfunction-associated fatty liver disease (MAFLD). This organelle, formed by the fusion of mitochondria and lysosomes, offers a novel pathway for breaking down damaged mitochondria, potentially influencing disease progression. Understanding MLRO's role could lead to innovative therapeutic strategies, although many questions about its mechanisms and implications in liver health remain unanswered. Read more about it below! #liverhealth #research #patientcare https://lnkd.in/ex4tr6_X

🌟New Study Reveals Key Determinant in Liver Disease! 🌍Non-alcoholic fatty liver disease (NAFLD) affects a third of the global population, leading to #LiverFibrosis, which significantly impacts disease severity and mortality. A recent study has now identified a crucial factor contributing to this condition. Researchers from Novartis (Novartis Biomedical Research, Basel) have used #CRISPR and #SpatialTranscriptomics technologies on primary human hepatic stellate cells to pinpoint ZNF469 as a key regulator of collagen expression, crucial for #LiverFibrosis in #NAFLD. This discovery was made through a comprehensive analysis involving transcriptional profiling of 108 human liver biopsies, covering the entire spectrum of #NAFLD. The #preprint study highlights how #ZNF469 directly interacts with genes and regulatory elements to control collagen levels and matrix homeostasis, marking it as a critical target for potential therapies. 💡 This breakthrough provides hope for better understanding and treating NAFLD-associated liver fibrosis, potentially saving millions of lives. 📖 Read the pre-print: https://hubs.ly/Q02vkkWS0 #Vizgen #MERSCOPE #LiverDisease

Excited to announce that my first doctoral thesis article titled "4-Hydroxybenzoic acid rescues multisystemic disease and perinatal lethality in a mouse model of mitochondrial disease" has been published! In this study, we generated a novel model of mitochondrial disease and identified a new therapeutic option based on endogenous CoQ biosynthesis stimulation. Hopefully, this research will pave the way for future advancements in treating patients affected by this condition. #MitochondrialDisease https://lnkd.in/dWJYyEz4

Excited to share our latest editorial with Dr. Milena Gulinac, MD, PhD: "Novel insights into autophagy in gastrointestinal pathologies, mechanisms in metabolic dysfunction-associated fatty liver disease and acute liver failure. Dive into our comprehensive exploration of three papers on the topic. 📑✨ Discover how our findings could pave the way for new therapeutic strategies. Don't miss out on these groundbreaking insights! #MedicalResearch #Gastroenterology #LiverDisease #Autophagy #ScientificInnovation #GROWTHresearchgroup #SUMMITproject #velikovamd 🔗 [https://lnkd.in/dmzhvzWg]

🔬 Exciting News! 📚 Thrilled to announce that a research paper from our group in IRCCS Policlinico di Sant’Orsola - Azienda Ospedaliero Universitaria di Bologna has been accepted by the Journal of Clinical Medicine (JCM) MDPI 🎉📄 💥 AUTOIMMUNE POLYENDOCRINE SYNDROMES IN ADULT ITALIAN CELIAC DISEASE PATIENTS💥 In this study, we delved into the prevalence of #autoimmune #polyendocrine syndromes in a cohort of patients with #celiac disease. Our findings emphasize the importance of a multidisciplinary management strategy for celiac patients, recognizing the intricate connections between different autoimmune conditions. 🔍 Understanding the "mosaic of autoimmunity" opens new avenues for comprehensive patient care and sheds light on the complex interplay of various autoimmune disorders within the same individual. 🤝 Grateful for the collaboration with fellow researchers and the support of our institution throughout this journey. Special thanks to the "Journal of Clinical Medicine" for providing a platform to share our insights. 📌 Looking forward to contributing more to the field of autoimmune research and advancing patient-centred approaches to healthcare. 💪🏼👩🔬👨⚕️ Free full text: https://lnkd.in/dMx2wDPu #Research #Autoimmunity #CeliacDisease #ClinicalMedicine #Healthcare #MedicalResearch #familyofautoimmunity #mosaicofautoimmunity

🧪 We are thrilled to announce that Rubió Metabolomics has contributed to a groundbreaking study published in the United European Gastroenterology Journal! 🧬 In collaboration with Dr. Paula Iruzubieta, Dr. Javier Crespo, and researchers from 7 Spanish hospitals, our scientific team has made significant strides in the field of hepatology. The study, titled "One‐step non‐invasive diagnosis of metabolic dysfunction‐associated steatohepatitis (MASH) and fibrosis in high‐risk population," highlights the effectiveness of our OWLiver Panel, which includes the innovative MASEF Score. This blood-based test has demonstrated high accuracy and performance, offering a powerful tool for diagnosing MASH and liver fibrosis, particularly in high-risk populations. Discover more about this important research and its potential impact on liver disease diagnosis. 🔗Read the full study here: https://lnkd.in/dTCXmNTG #Hepatology #Metabolomics #LiverHealth #MedicalResearch #OWLMetabolomics #HealthcareInnovation

In this episode (#302) of The Drive, I speak with Julia Wattacheril, M.D., M.P.H., a physician scientist and director of the Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) program at Columbia University Irving Medical Center. We delve deep into the complex world of liver health, beginning with a foundational overview of liver physiology. Julia provides an in-depth look at how alcohol impacts liver function, breaking down the metabolism of ethanol and its detrimental effects. Julia then shifts the focus to understanding liver function tests and optimal enzyme levels, providing a detailed explanation of AST and ALT and elucidating why fluctuations in these levels may or may not be concerning. Here’s a glimpse of what we discuss: - The complex and crucial functionality of the liver, its four most essential functions, and more - Methods of diagnosing liver disease and how insights guide treatment and management strategies - Potential impact of recreational drugs, statins, and other medications on liver function test results - The impact of fructose consumption on liver health and the challenges of disentangling its effects from other factors like obesity and insulin resistance - Emerging drugs and therapies for addressing fat accumulation and fibrosis related to MAFLD - More https://bit.ly/3V6pnCU

Exciting news in @HEPJournal from director Arun Sanyal and a team of international all ⭐ colleagues! A milestone in non-invasively identifying at-risk MASH -- The metabolomics-advanced steatohepatitis fibrosis score (MASF score) can accurately identify metabolic dysfunction-associated steatohepatitis (MASLD) with ≥F2 fibrosis (at-risk MASH). 🔬The MASEF score, based on a unique combination of serum-based metabolomics and clinical data and developed by our partner, OWL Metabolomics, offers a new level of precision in diagnosing MASH. #liver https://bit.ly/47yPB4j